Bal Pharma Ltd

Bal Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Bal Pharma Ltd

₹ 86.2 -1.01%
05 Jun - close price
balpharma.com BSE: 524824 NSE: BALPHARMA
About

Incorporated in 1987, Bal Pharma Ltd does manufacturing and selling of pharmaceutical products and related services[1]

Key Points

Business Overview:[1]
BALPL is a fully integrated pharmaceuticals company specialising in Bulk Drugs, Prescription Drugs, Generics, Pharma intermediates, and Ayurvedic products. Company focuses on therapeutic areas viz. Anti-diabetes, Anti-histamine, Anti-inflammatory, Acne Treatment, Gastroenterology, Cardiology, and dermatology. Company is one of Gliclazide's largest producers and exporters, a medicine to treat type-2 diabetes.

Website BSE NSE
  • Market Cap ₹ 137 Cr.
  • Current Price ₹ 86.2
  • High / Low ₹ 113 / 59.7
  • Stock P/E 21.9
  • Book Value ₹ 51.6
  • Dividend Yield 1.39 %
  • ROCE 9.69 %
  • ROE 7.87 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 4.46% over past five years.
  • Tax rate seems low
  • Company has a low return on equity of 9.37% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
82.45 70.39 92.54 81.66 94.63 74.36 73.69 73.15 81.88 65.87 74.02 87.69 84.08
74.29 63.95 84.84 73.87 85.03 67.89 66.00 65.40 74.24 59.81 68.29 78.15 73.50
Operating Profit 8.16 6.44 7.70 7.79 9.60 6.47 7.69 7.75 7.64 6.06 5.73 9.54 10.58
OPM % 9.90% 9.15% 8.32% 9.54% 10.14% 8.70% 10.44% 10.59% 9.33% 9.20% 7.74% 10.88% 12.58%
0.19 0.16 0.14 0.10 2.45 0.82 -0.20 0.51 1.08 0.72 1.12 0.33 -0.24
Interest 3.85 3.64 3.82 3.66 4.14 4.24 3.65 5.01 3.95 4.05 3.86 4.85 4.06
Depreciation 2.09 2.53 2.42 2.96 2.16 2.43 2.48 2.69 2.18 2.52 2.27 3.23 3.06
Profit before tax 2.41 0.43 1.60 1.27 5.75 0.62 1.36 0.56 2.59 0.21 0.72 1.79 3.22
Tax % 32.78% 79.07% 39.38% 33.07% 3.65% 58.06% 23.53% 7.14% -108.88% 0.00% 0.00% 0.00% -12.11%
1.62 0.09 0.97 0.85 5.53 0.26 1.04 0.52 5.41 0.21 0.72 1.79 3.60
EPS in Rs 1.02 0.05 0.61 0.56 3.46 0.16 0.65 0.30 3.41 0.13 0.45 1.12 2.25
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
187 198 229 211 225 171 251 281 304 339 303 312
170 183 214 194 207 166 226 257 279 308 273 280
Operating Profit 17 15 15 17 18 5 25 24 25 31 30 32
OPM % 9% 7% 6% 8% 8% 3% 10% 9% 8% 9% 10% 10%
1 1 3 2 1 2 1 5 1 3 2 2
Interest 7 6 8 9 13 13 12 11 12 15 17 17
Depreciation 7 7 6 7 6 8 10 9 9 10 10 11
Profit before tax 5 3 3 3 -0 -14 4 9 5 9 5 6
Tax % 25% 90% 114% 87% -1,175% -5% -15% 38% 45% 18% -41% -7%
4 1 -0 0 2 -13 5 6 3 7 7 6
EPS in Rs 2.82 1.10 1.24 1.96 2.67 -8.62 3.20 3.78 1.64 4.68 4.53 3.94
Dividend Payout % 35% 91% 81% 51% 37% 0% 31% 26% 61% 26% 26% 0%
Compounded Sales Growth
10 Years: 5%
5 Years: 4%
3 Years: 1%
TTM: 3%
Compounded Profit Growth
10 Years: 16%
5 Years: 6%
3 Years: 35%
TTM: -13%
Stock Price CAGR
10 Years: 0%
5 Years: -2%
3 Years: -1%
1 Year: -14%
Return on Equity
10 Years: 5%
5 Years: 8%
3 Years: 9%
Last Year: 8%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 13 13 14 14 14 14 15 15 16 16 16 16
Reserves 42 42 48 51 52 38 39 44 48 56 62 66
49 89 93 110 124 118 110 104 131 140 150 160
59 67 78 86 71 68 76 98 116 108 108 134
Total Liabilities 164 211 233 260 261 238 240 261 311 320 336 376
52 56 60 71 70 71 69 67 76 80 87 94
CWIP 1 4 2 0 4 3 0 2 0 0 3 7
Investments 0 0 0 0 0 0 0 0 0 7 2 2
111 151 172 188 187 164 172 192 235 233 244 272
Total Assets 164 211 233 260 261 238 240 261 311 320 336 376

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
15 -19 6 1 8 23 22 27 -2 23 20 30
-5 -14 -8 -4 -8 -5 -6 -9 -22 -19 -15 -21
-7 32 -6 4 0 -20 -17 -17 24 -1 -8 -10
Net Cash Flow 2 -1 -8 1 -0 -2 0 0 0 3 -2 0
Free Cash Flow 9 -34 -2 -3 -1 18 19 18 -16 12 2 8
CFO/OP 93% -125% 52% 11% 57% 465% 91% 117% -4% 88% 75% 95%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 88 105 99 111 105 106 98 98 113 107 111 110
Inventory Days 132 145 172 240 217 292 146 162 207 167 238 269
Days Payable 142 163 171 182 147 167 114 143 167 147 189 206
Cash Conversion Cycle 78 87 100 168 175 231 130 117 153 127 161 173
Working Capital Days 14 50 26 45 25 -11 11 18 13 12 6 7
ROCE % 11% 7% 8% 8% 7% -0% 10% 12% 10% 12% 10% 10%

Insights

In beta
Mar 2015 Mar 2019 Feb 2023 Mar 2024 Jun 2025
Number of Operational Manufacturing Units
Units ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Total Employee Strength
Number ・Standalone data
API Business Order Book
Rs Million ・Standalone data
Number of Active API Molecules
Number
Number of Generic Formulations
Number
Doctor Reach
Number
Field Force Size
Number
Formulations Business Order Book
Rs Million ・Standalone data
Number of Registrations Worldwide
Number
Total Installed API and Intermediates Capacity
TPA
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
51.61% 51.61% 51.24% 51.24% 51.24% 50.87% 50.87% 50.87% 50.87% 50.87% 50.87% 50.87%
0.17% 0.14% 0.13% 0.13% 0.13% 0.13% 0.14% 0.14% 0.15% 0.23% 0.14% 0.14%
48.23% 48.25% 48.64% 48.64% 48.63% 49.01% 49.00% 49.01% 48.99% 48.91% 49.01% 49.01%
No. of Shareholders 15,86915,52915,06014,77215,01416,00715,66715,72315,82615,77415,52015,214

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue

Credit ratings

Concalls

  • Feb 2023
    Transcript
    AI Summary
    PPT
  • Sep 2022
    Transcript
    AI Summary
    PPT
  • Sep 2022
    Transcript
    AI Summary
    PPT